• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PD-1 and CTLA4: Two checkpoints, one pathway?

作者信息

Walker Lucy S K

机构信息

Institute of Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London, UK NW3 2PF.

出版信息

Sci Immunol. 2017 May 12;2(11). doi: 10.1126/sciimmunol.aan3864.

DOI:10.1126/sciimmunol.aan3864
PMID:28529997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5436606/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f401/5436606/a7900689fe20/emss-72821-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f401/5436606/a7900689fe20/emss-72821-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f401/5436606/a7900689fe20/emss-72821-f001.jpg

相似文献

1
PD-1 and CTLA4: Two checkpoints, one pathway?程序性死亡受体1（PD-1）与细胞毒性T淋巴细胞相关抗原4（CTLA4）：两个检查点，同一条信号通路？
Sci Immunol. 2017 May 12;2(11). doi: 10.1126/sciimmunol.aan3864.
2
Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model.大鼠胆管癌模型中免疫检查点DNA癌症疫苗的综合评估
Vaccines (Basel). 2020 Nov 24;8(4):703. doi: 10.3390/vaccines8040703.
3
Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.膀胱尿路上皮癌中免疫检查点相关分子的信使核糖核酸表达与蛋白质表达的相关性：一项回顾性研究。
Urol Oncol. 2017 May;35(5):257-263. doi: 10.1016/j.urolonc.2017.01.014. Epub 2017 Mar 11.
4
[Expression of immune checkpoints PD-L1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].[根据错配修复状态，免疫检查点PD-L1、CTLA4、LAG3在结肠腺癌微环境中的表达]
Arkh Patol. 2024;86(2):6-13. doi: 10.17116/patol2024860216.
5
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.放疗和双重检查点阻断激活癌症中的非冗余免疫机制。
Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.
6
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1 Activated T Cells.一种增强CTLA4对PD-1激活T细胞阻断作用的单价双特异性PD-1/CTLA4抗体的设计与疗效
Cancer Discov. 2021 May;11(5):1100-1117. doi: 10.1158/2159-8290.CD-20-1445. Epub 2021 Jan 8.
7
Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.肿瘤细胞内在 CTLA4 调控非小细胞肺癌中的 PD-L1 表达。
J Cell Mol Med. 2019 Jan;23(1):535-542. doi: 10.1111/jcmm.13956. Epub 2018 Oct 30.
8
Identification of the Prognosis Value and Potential Mechanism of Immune Checkpoints in Renal Clear Cell Carcinoma Microenvironment.肾透明细胞癌微环境中免疫检查点的预后价值及潜在机制的鉴定
Front Oncol. 2021 Jul 14;11:720125. doi: 10.3389/fonc.2021.720125. eCollection 2021.
9
Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.转移性肾细胞癌中腺苷 2A 受体的表达增加与对血管内皮生长因子抑制剂和抗 PD-1/抗 CTLA4 抗体的反应较差以及生存时间较短相关。
Cancer Immunol Immunother. 2021 Jul;70(7):2009-2021. doi: 10.1007/s00262-020-02843-x. Epub 2021 Jan 8.
10
Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study.异常 PD-1 和 CTLA4 表达对癌症免疫和预后的临床意义：泛癌症研究。
Front Immunol. 2020 Sep 10;11:2048. doi: 10.3389/fimmu.2020.02048. eCollection 2020.

引用本文的文献

1
Costimulatory connections: CARMIL2 and CD28.共刺激连接：CARMIL2和CD28。
J Exp Med. 2025 Aug 4;222(8). doi: 10.1084/jem.20250896. Epub 2025 Jun 20.
2
LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy.LSD1：改变肿瘤微环境和增强免疫检查点治疗的新兴面孔。
J Biomed Sci. 2023 Jul 31;30(1):60. doi: 10.1186/s12929-023-00952-0.
3
PD-1 and CTLA-4 exert additive control of effector regulatory T cells at homeostasis.PD-1 和 CTLA-4 在稳态下对效应调节性 T 细胞发挥累加控制作用。

本文引用的文献

1
Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.新发1型糖尿病中CD8 T细胞的部分耗竭及替普珠单抗的临床反应
Sci Immunol. 2016 Nov;1(5). doi: 10.1126/sciimmunol.aai7793. Epub 2016 Nov 18.
2
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.通过靶向PD-1疗法挽救耗竭的CD8 T细胞是依赖CD28的。
Science. 2017 Mar 31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9.
3
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
Front Immunol. 2023 Mar 7;14:997376. doi: 10.3389/fimmu.2023.997376. eCollection 2023.
4
Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood.利用外周血治疗前和治疗后的免疫表型分析对黑色素瘤中PD-1阻断反应进行分层。
Immunother Adv. 2023 Jan 6;3(1):ltad001. doi: 10.1093/immadv/ltad001. eCollection 2023.
5
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges.肝细胞癌中的免疫检查点抑制剂：当前进展与挑战
Front Oncol. 2021 Oct 22;11:737497. doi: 10.3389/fonc.2021.737497. eCollection 2021.
6
Regulation of the immune tolerance system determines the susceptibility to HLA-mediated abacavir-induced skin toxicity.免疫耐受系统的调节决定了对 HLA 介导的阿巴卡韦诱导的皮肤毒性的易感性。
Commun Biol. 2021 Sep 28;4(1):1137. doi: 10.1038/s42003-021-02657-2.
7
Using Machine Learning Modeling to Explore New Immune-Related Prognostic Markers in Non-Small Cell Lung Cancer.使用机器学习建模探索非小细胞肺癌新的免疫相关预后标志物。
Front Oncol. 2020 Oct 30;10:550002. doi: 10.3389/fonc.2020.550002. eCollection 2020.
8
Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting?癌症中调节性T细胞的转录调控：走向治疗靶点？
Cancers (Basel). 2020 Oct 30;12(11):3194. doi: 10.3390/cancers12113194.
9
Targeting co-stimulatory molecules in autoimmune disease.针对自身免疫性疾病中的共刺激分子。
Nat Rev Drug Discov. 2020 Dec;19(12):860-883. doi: 10.1038/s41573-020-0081-9. Epub 2020 Sep 16.
10
Exhausted CD4 T Cells during Malaria Exhibit Reduced mTORc1 Activity Correlated with Loss of T-bet Expression.在疟疾期间耗尽的 CD4 T 细胞表现出降低的 mTORc1 活性，与 T-bet 表达的丧失相关。
J Immunol. 2020 Sep 15;205(6):1608-1619. doi: 10.4049/jimmunol.2000450. Epub 2020 Aug 17.
T细胞共刺激受体CD28是PD-1介导抑制作用的主要靶点。
Science. 2017 Mar 31;355(6332):1428-1433. doi: 10.1126/science.aaf1292. Epub 2017 Mar 9.
4
The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness.TCF1-Bcl6轴可对抗I型干扰素，以抑制耗竭并维持T细胞干性。
Sci Immunol. 2016 Dec 23;1(6). doi: 10.1126/sciimmunol.aai8593. Epub 2016 Dec 9.
5
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.定义在PD-1治疗后提供增殖爆发的CD8+ T细胞。
Nature. 2016 Sep 15;537(7620):417-421. doi: 10.1038/nature19330. Epub 2016 Aug 2.
6
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model.新型自身免疫性胰腺炎小鼠模型中PD-1和FoxP3在维持免疫耐受中的非重叠作用
Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):8490-5. doi: 10.1073/pnas.1608873113. Epub 2016 Jul 7.
7
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.程序性细胞死亡蛋白 1 形成负性共刺激微簇，通过募集磷酸酶 SHP2 直接抑制 T 细胞受体信号转导。
J Exp Med. 2012 Jun 4;209(6):1201-17. doi: 10.1084/jem.20112741. Epub 2012 May 28.
8
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.CTLA4 作为 T 细胞反应的细胞外在调节因子的新兴作用。
Nat Rev Immunol. 2011 Nov 25;11(12):852-63. doi: 10.1038/nri3108.
9
Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation.CTLA-4基因敲除小鼠自身免疫性疾病的诱导取决于体内共刺激所需的特定CD28基序。
Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13756-61. doi: 10.1073/pnas.0706509104. Epub 2007 Aug 16.
10
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.程序性死亡受体1（PD-1）免疫受体通过招募含src同源2结构域的酪氨酸磷酸酶2至磷酸酪氨酸来抑制B细胞受体介导的信号传导。
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13866-71. doi: 10.1073/pnas.231486598. Epub 2001 Nov 6.